Xcout IntelLifesenz Cancer
Lifesenz Cancer is a biomedical organization that develops 3D cell culture systems and patient-derived ex vivo models to predict individual chemotherapy responses and guide precision cancer therapy. The company also provides biopharmaceutical R&D training, workshops, and educational programs for students, researchers, and job seekers to bridge the gap between academia and industry.
Subscribe to see Lifesenz Cancer’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Lifesenz Cancer at a glance
Lifesenz Cancer is a biotechnology company headquartered in India. Xcout tracks 5 named people at Lifesenz Cancer, including Dr. Arindam Banerjee (CEO and Director).
Lifesenz Cancer leadership
- Dr. Arindam BanerjeeCEO and Director
- Prof Peter E LobieProfessor & Co-Director
- Dr. Aditya MankeFounder, Senior Onco Surgeon
- Mr. Hanskumar ShahDirector
- Mr. Kaushik ShahDirector
Recent Lifesenz Cancer news
Lifesenz Cancer competitors
A few of Lifesenz Cancer's closest competitors — see the full list of competitors and alternatives →
Origin Bio operates a tissue-first data and model platform that maps cancer biology using patient tumor samples. The company generates spatial, molecular, and functional maps from real tumor tissue to support target discovery, drug response prediction, and multimodal AI modeling for researchers and life sciences partners.
Novigenix is an immuno-transcriptomics and TechBio company that provides precision oncology solutions for biopharmaceutical companies and researchers. It offers LITOseek, an AI-powered liquid biopsy platform that analyzes gene activity in immune cells to support biomarker discovery, therapy development, and patient response monitoring.
WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Indivumed GmbH is a precision oncology company that provides tumor and normal tissue samples, multi-omics and clinical data databases, biomathematical and AI tools, and patient-derived cellular models. The company serves researchers and pharmaceutical partners by conducting cancer target discovery, target validation, and therapeutic drug development.
Parallel Bio provides a human-first drug discovery and precision medicine platform that maps human biology using patient samples and computational tools. The company serves pharmaceutical and biotechnology organizations by conducting faster, animal-free preclinical testing and generating proprietary human biological data.
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Get Lifesenz Cancer's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Lifesenz Cancer in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access